Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by itntdfon Dec 07, 2023 11:11am
138 Views
Post# 35773052

RE:RE:RE:RE:New Press Release - Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS

RE:RE:RE:RE:New Press Release - Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
LOS ANGELES, Sept. 29, 2023 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer, is thrilled that the U.S. House of Representatives approved an amendment to the Defense Appropriations Bill, increasing funding for the dedicated Pancreatic Cancer Research Program at the Department of Defense (DoD) from $15 to $20 million for the new fiscal year in their version of the bill. In order for this funding increase to get enacted into law, the Senate will need to advance their version of the bill and the increase will need to be kept intact throughout conference negotiations between both chambers.
 
As a result of PanCAN's ongoing advocacy efforts, the House Defense Appropriations committee included $15 million for the Pancreatic Cancer Research Program when the Fiscal Year (FY) 24 Defense Appropriations Act was reported out of committee. As the bill was advancing to final passage, Representative Terri Sewell (D-AL) supported by Representatives Anna Eshoo (D-CA), Andre Carson (D-IN) and John Joyce (R-PA) introduced an amendment to increase funding for the program by $5 million. The full House responded in support and the FY 24 Defense Appropriations Act was passed by the House with $20 million dedicated to pancreatic cancer research. While this is a critical milestone, PanCAN will continue to advocate to ensure the increase is included as the bill moves through next steps with the Senate and conference negotiations.
<< Previous
Bullboard Posts
Next >>